Search Results

You are looking at 1 - 10 of 16 items for :

  • pharmacokinetics x
Clear All
Open access

Patrick M. Honoré, Rita Jacobs, Elisabeth De Waele, Jouke De Regt, Thomas Rose and Herbert D. Spapen

References 1. Sefar S, Degoricija V. About drug dialyzability. Acta Clin Croat 2003;42:257-26. 2. Al-Habet SM, Rogers HJ. Methylprednisolone pharmacokinetics after intravenous and oral administration. Br J Clin Pharmacol 1989;27:285-90. 3. Venkatesh B, Myburgh J, Finfer S, Webb SA, Cohen J, Bellomo R, et al. The ADRENAL study protocol: Adjunctive corticosteroid treatment in critically ill patients with septic shock. Crit Care Resusc 2013;15:83-8. 4. Frey BM, Frey FJ. Clinical pharmacokinetics of

Open access

Patrick M. Honore, Rita Jacobs, Olivier Joannes-Boyau, Willem Boer, Elisabeth De Waele, Viola Van Gorp and Herbert D. Spapen

References 1. Spapen HD, Jacobs R, Van Gorp V, Troubleyn J, Honoré PM. Renal and neurological side effects of colistin in critically ill patients. Ann Intensive Care 2011;1:14. 2. Bergen PJ, Li J, Rayner CR, Nation RL. Colistin methanesulfonate is an inactive prodrug of colistin against Pseudomonas aeruginosa.Antimicrob Agents Chemother 2006;50:1953-8. 3. Couet W, Grégoire N, Marchand S, Mimoz O. Colistin pharmacokinetics: The fog is lifting. Clin Microbiol Infect 2012;18:30-9. 4. Yahav D

Open access

Ayman Geddawy, Yasmine F. Ibrahim, Nabil M. Elbahie and Mohammad A. Ibrahim

approved in combination with PegIFN-alpha and ribavirin for the treatment of chronic HCV genotype 1 infection in 2011. [7] However, these drugs have been reported to have several drug-drug interactions, and are largely replaced with newer DAA including Simeprevir, Paritaprevir, Daclatasvir, Ledipasvir, Ombitasvir, Sofosbuvir and Dasabuvir. Table 3 summarizes the pharmacokinetics of all approved DAA with special reference to the sites of drug-drug interaction. Clinical pharmacology of the newer DAA will be discussed in the next section. Table 3 Pharmacokinetics

Open access

Patrick M. Honore, Rita Jacobs, Olivier Joannes-Boyau, Elisabeth De Waele and Herbert D. Spapen

. Endocrinology in Intensive Care Medicine: New Insights and Therapeutic Consequences. Verh K Acad Geneeskd Belg 2002;64:167-87. 16. Amer MR, Akhras NS, Mahmood WA, Al-Jazairi AS. Antimicrobial Stewardship Program Implementation in a medical intensive care unit in a tertiary hospital in Saudi Arabia. Ann Saudi Med 2013;33:547-54. 17. Honore PM, Jacobs R, Spapen HD. Impact of altered antimicrobial pharmacokinetics on antimicrobial dosing during extracorporeal membrane oxygenation. Annu Update Intensive Care Emerg Med 2014;34 [In Press

Open access

He Sun, Xin Su and Yi Shi

posaconazole in experimental models of invasive fungal infections. Mycoses 2006;49:S7-16. 14. Petraitiene R, Petraitis V, Groll AH, Sein T, Piscitelli S, Candelario M, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: Correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001;45:857-69. 15. Graybill JR, Hernandez S, Bocanegra R, Najvar LK. Antifungal therapy of murine Aspergillus terreus infection. Antimicrob Agents

Open access

Nicoletta Riva and Walter Ageno

favorable data on the DOACs but they are not licensed for this indication yet. However, it should be remembered that rivaroxaban is contraindicated in patients with advanced cirrhosis (Child class B and C), after a pharmacokinetic study showed increased rivaroxaban concentrations in patients with moderate hepatic impairment;[ 32 , 33 ] while apixaban has the highest percentage of hepatic metabolism (up to 73%) and therefore should be used with caution in patients with mild or moderate liver impairment (Child class A and B), it is not recommended in patients with severe

Open access

Patrick M. Honore and Herbert D. Spapen

e3182816a75 Honore PM Jacobs R Joannes-Boyau O De Regt J De Waele E van Gorp V Newly designed CRRT membranes for sepsis and SIRS--a pragmatic approach for bedside intensivists summarizing the more recent advances: a systematic structured review ASAIO J 2013 59 99 106 16 Honore PM, Jacobs R, De Waele E, Spapen HD. Applying pharmacokinetic/pharmacodynamic principles for optimizing antimicrobial therapy during continuous renal replacement therapy. Anaesthesiol Intensive Ther 2017; 49: 412-8. 10.5603/AIT.a2017.0071 Honore PM Jacobs R De Waele E Spapen HD. Applying

Open access

Ya-ling Han

the definition, mechanism, clinical impacts, detection, and intervention of aspirin resistance. Definition of Aspirin Resistance The concept of aspirin therapy response variability is mainly based on specific pathophysiological mechanisms, pharmacokinetics, and/ or pharmacodynamics by which aspirin works. aspirin resistance may be simply one of potential causes leading to interindividual variability in the response to aspirin. [ 1 ] In 2009, the Working Group on Thrombosis of the European Society of Cardiology released a position paper on interindividual

Open access

Xiangbo Xu, Zhaohui Bai, Qingchun Zhao, Hongyu Li, Qiang Shi, Jiao Deng, Jingqiao Zhang, Xiaozhong Guo and Xingshun Qi

Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis Indian J Crit Care Med 1992 20 864 74 11 Seymour CW, Rosengart MR. Septic Shock: Advances in Diagnosis and Treatment. JAMA 2015; 314: 708-17. 10.1001/jama.2015.7885 Seymour CW Rosengart MR Septic Shock: Advances in Diagnosis and Treatment JAMA 2015 314 708 17 12 Wiseman LR, Wagstaff AJ, Brogden RN, Bryson HM. Meropenem. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. Drugs 1995

Open access

Armando Peixoto, Marco Silva, Rui Gaspar, Rui Morais, Rosa Ramalho, Guilherme Macedo and João Santos-Antunes

] low compliance, [ 4 ] and hypersecretion of hydrochloric acid. [ 5 ] However, the evidence is scarce for other factors, particularly the impact biotype, [ 6 ] smoking, [ 7 ] diabetes mellitus (DM), [ 8 ] and previous treatment failure. In particular, it is unknown whether the body mass index (BMI) influences in a clinically significant way the pharmacokinetics and/or pharmacodynamics of the drugs involved in eradication (in particular, the proton pump inhibitors and antibiotics). Furthermore, to date, studies are in most cases controlled in relation to the